Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estimabl: Strategies for Radioiodine Ablation in Thyroid Carcinoma
NCT00435851Phase 3Unknown
- Sponsor
- Gustave Roussy
- Start
- Feb 2007
- Modality
- Biologic, rProtein (Recombinant Protein), Hormone
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thyrotropin alfa in differentiated thyroid carcinoma (DTC), sponsored by Gustave Roussy. Primary endpoint: Rate of successful postoperative thyroid ablation at 10 months. Status: unknown.
02
Drugs
thyrotropin alfa
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT00435851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00435851.